Vitae to collaborate with GSK

Vitae Pharmaceuticals of Fort Washington, PA has inked a deal to collaborate with GlaxoSmithKline on developing drugs for hypertension and other cardiovascular diseases. Vitae gains an unspecified upfront payment and a deal that is worth up to $175 million for a successful development program.

"Offering significant potency and oral availability, our unique renin inhibitor compounds show promise as a breakthrough treatment for hypertension. We are very excited to work with GSK to create best-in-class medicines that make a difference and meaningfully improve patient outcomes," said Jeffrey Hatfield, CEO of Vitae.

- read this release for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.